4-氨基-3-甲基氨基苯甲腈 | 64910-49-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-3-甲基氨基苯甲腈
• 英文名称: 4-amino-3-(methylamino)benzonitrile
• 英文别名: 4-amino-3-methylaminobenzonitrile；3-(methylamino)-4-aminobenzonitrile；4-amino-3-methylamino-benzonitrile；4-Amino-3-methylamino-benzonitril；4-Amino-3-methylaminobenzonitril
• CAS: 64910-49-2
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: NRISBPKZFFXEHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氨基-3-甲基氨基苯甲腈 在 10percent Pd/C 氢气 、 羟胺 、 溶剂黄146 、 对苯醌 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 7.83h， 生成 2-(2-Hydroxy-biphenyl-3-yl)-3-methyl-3H-benzoimidazole-5-carboxamidine
  参考文献：
  名称：

  Development of Serine Protease Inhibitors Displaying a Multicentered Short (<2.3 Å) Hydrogen Bond Binding Mode:  Inhibitors of Urokinase-Type Plasminogen Activator and Factor Xa

  摘要：

  Novel scaffolds that bind to serine proteases through a unique network of short hydrogen bonds to the catalytic Ser195 have been developed. The resulting potent serine protease inhibitors were designed from lead molecule 2-(2-hydroxyphenyl)1H-benzoimidazole-5-carboxamidine, 6b, which is known to display several modes of binding. For instance, 6b can recruit zinc and bind in a manner similar to that reported by bis(5-amidino-2-benzimidazolyl)methane (BABIM) (Nature 1998, 391, 608-612).(1) Alternatively, 6b can bind in the absence of zinc through a multicentered network of short (<2.3 Angstrom) hydrogen bonds. The lead structure was optimized in the zinc-independent binding mode toward a panel of six human serine proteases to yield optimized inhibitors such as 2-(3-bromo-2-hydroxy-5-methylphenyl)-1H-indole-5-carboxamidine, 22a, and 2-(2-hydroxybiphenyl-3-yl)-1H-indole-5-carboxamidine, 22f. Structure-activity relationships determined that, apart from the amidine function, an indole or benzimidazole and an ortho substituted phenol group were also essential components for optimal potency. The affinities (K-i) of 22a and 22f, for example, bearing these groups ranged from 8 to 600 nM toward a panel of six human serine proteases. High-resolution crystal structures revealed that the binding mode of these molecules in several of the enzymes was identical to that of 6b and involved short (<2.3 Angstrom) hydrogen bonds among the inhibitor hydroxyl oxygen, Ser195, and a water molecule trapped in the oxyanion hole. In summation, novel and potent trypsin-like serine protease inhibitors possessing a unique mode of binding have been discovered.

  DOI：

  10.1021/jm0100638
• 作为产物：
  描述：

  3-氯-4-硝基苯甲腈 在 盐酸 、 tin(II) chloride dihydrate 作用下， 以 甲醇 、 乙腈 为溶剂， 170.0 ℃ 、4.0 MPa 条件下， 反应 0.5h， 生成 4-氨基-3-甲基氨基苯甲腈
  参考文献：
  名称：

  作为微管蛋白聚合抑制剂的新型苯并咪唑丙烯腈的合成、计算分析和抗增殖活性：第 2 部分

  摘要：

  我们使用经典的线性和微波辅助合成方法制备了新型N-取代的苯并咪唑衍生的丙烯腈，其在体外对多种癌细胞具有抗增殖活性。最有效的系统对所有测试的血液癌细胞系均表现出显着的活性，并对正常细胞具有良好的选择性。还对先导化合物的选择进行了体外测试，以抑制微管蛋白聚合，作为可能的生物作用机制。对接和分子动力学模拟的结合证实了所采用的有机骨架对于抗肿瘤药物设计的适用性，并证明其生物活性依赖于与微管蛋白中秋水仙碱结合位点的结合。此外，它还强调，较高的微管蛋白亲和力与（i）苯并咪唑氮上较大的烷基和芳基部分以及（ii）苯基上的供电子取代基有关，这些取代基允许更深入地进入微管蛋白β-内的疏水口袋。亚基，由 Leu255、Leu248、Met259、Ala354 和 Ile378 残基组成。

  DOI：

  10.3390/ph14101052

文献信息

• Cu-Catalyzed C–H Allylation of Benzimidazoles with Allenes
  作者：Yaxi Dong、Bernhard Breit

  DOI：10.1021/acs.orglett.1c02346

  日期：2021.9.3

  CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A

  已经描述了 CuH 催化的苯并咪唑与丙二烯的分子内环化和分子间烯丙基化。在Cu(OAc) 2 /Xantphos的催化体系和催化量的(MeO) 2 MeSiH的作用下，反应顺利进行。该协议具有温和的反应条件和对带有吸电子、给电子或电子中性基团的底物的良好耐受性。针对该氢化铜催化体系提出了一种新的催化机理。
• Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
  申请人：Mjalli Adnan M. M.

  公开号：US20110201604A1

  公开（公告）日：2011-08-18

  Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.

  提供了替代融合咪唑衍生物、其制备方法、包含替代融合咪唑衍生物的药物组合物，以及在治疗炎症中使用的方法。这些替代融合咪唑衍生物可能控制血红素氧合酶的活性或数量，或者同时控制活性和数量。
• [EN] NOVEL CHEMICAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005082901A1

  公开（公告）日：2005-09-09

  This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.

  这项发明涉及新识别的化合物，用于抑制hYAK3蛋白，并用于治疗与hYAK3蛋白不平衡或不适当活性相关的疾病的方法。
• Novel Chemical Compounds
  申请人：Duffy J. Kevin

  公开号：US20070249599A1

  公开（公告）日：2007-10-25

  This invention relates to the newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.

  本发明涉及一种新鉴定的化合物，用于抑制hYAK3蛋白质并治疗与hYAK3蛋白质不平衡或不适当活性相关的疾病的方法。
• THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS
  申请人：Dhanak Dashyant

  公开号：US20090048252A1

  公开（公告）日：2009-02-19

  Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones.

  本发明涉及使用取代噻唑酮抑制PI3激酶活性/功能的方法。同时本发明涉及使用取代噻唑酮治疗以下一种或多种疾病状态的方法：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官衰竭、肾脏疾病、血小板聚集、癌症、精子活动力低下、移植排斥、移植物排斥和肺损伤。